专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008145689A1 H-FABP AS EARLY PREDICTOR OF MYOCARDIAL INFARCTION 审中-公开
标题翻译： H-FABP作为心肌梗塞的早期预后因素
公开(公告)号：WO2008145689A1
公开(公告)日：2008-12-04
申请号：PCT/EP2008/056603
申请日：2008-05-29
申请人： F. HOFFMANN LA-ROCHE AG , ROCHE DIAGNOSTICS GMBH , HESS, Georg , HÜDIG, Hendrik , KIENTSCH-ENGEL, Rosemarie , ZDUNEK, Dietmar
发明人： HESS, Georg , HÜDIG, Hendrik , KIENTSCH-ENGEL, Rosemarie , ZDUNEK, Dietmar
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2800/324
摘要： The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac Troponin level, which is detectable, but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac Troponin level which is detectable, but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of H-FABP and, optionally, myoglobin in a sample of said subject and comparing the amount of H-FABP and, optionally, myoglobin to reference amounts. Also comprised by the present invention are kits or devices to carry out the methods of the present invention.
摘要翻译：本发明涉及一种用于诊断患有急性冠状动脉综合征且具有心肌肌钙蛋白水平的受试者的心肌梗塞的方法，其可检测但低于被认为是指示心肌梗死的水平。此外，本发明涉及用于识别易受心脏干预的受试者的方法，其中所述受试者患有急性冠状动脉综合征，并且具有心脏肌钙蛋白水平，其可检测但低于被认为是指示心肌梗死本发明的方法是基于所述受试者的样品中H-FABP和任选的肌红蛋白的测定，并将H-FABP和任选的肌红蛋白的量与参考量进行比较。本发明还包括用于实施本发明方法的试剂盒或装置。

2. 发明申请

WO1995023801A1 INTERFERENCE SUPPRESSION AGENT FOR USE IN IMMUNO ASSAYING 审中-公开
标题翻译：噪声抑制器使用免疫测定法
公开(公告)号：WO1995023801A1
公开(公告)日：1995-09-08
申请号：PCT/EP1995000776
申请日：1995-03-03
申请人： BOEHRINGER MANNHEIM GMBH , KIENTSCH-ENGEL, Rosemarie , DONIE, Frederic , WIEDMANN, Michael
发明人： BOEHRINGER MANNHEIM GMBH
IPC分类号： C07D495/04
CPC分类号： C07D495/04 , G01N33/5306 , Y10S435/962 , Y10S436/824 , Y10S436/825 , Y10T436/25125
摘要： The object of the invention comprises interference suppression agents for preventing non-specific interactions in immuno assaying, in which avidine or streptavidine or a derivative thereof is used as interference suppression agents.
摘要翻译：本发明涉及抗干扰，以避免在免疫测定中的非特异性相互作用，被用作干扰降低抗生物素蛋白或链霉或其衍生物装置。

3. 发明申请

WO9703704A3 IN VIVO DIABETES TEST 审中-公开
标题翻译：血糖测试
公开(公告)号：WO9703704A3
公开(公告)日：1997-06-05
申请号：PCT/EP9603192
申请日：1996-07-19
申请人： BOEHRINGER MANNHEIM GMBH , ENDL JOSEF , GANZ MANFRED , STAHL PETER , KIENTSCH ENGEL ROSEMARIE , JUNG GUENTHER GERHARD , POZZILLI PAOLO , DONIE FREDERIC
发明人： ENDL JOSEF , GANZ MANFRED , STAHL PETER , KIENTSCH-ENGEL ROSEMARIE , JUNG GUENTHER-GERHARD , POZZILLI PAOLO , DONIE FREDERIC
IPC分类号： A61K49/00 , C12N9/88 , G01N33/564 , G01N33/574 , G01N33/68 , G01N33/74
CPC分类号： G01N33/6893 , A61K49/0006 , C12N9/88 , G01N33/564 , G01N33/574 , G01N33/74 , G01N2800/042
摘要： The invention concerns the use of substances which react together to prepare an agent for the diagnosis of cell-transmitted diseases or a predisposition towards such diseases, the agent being applied intradermally and the diagnosis being made on the basis of the appearance or absence of a positive reaction at the point of application.
摘要翻译：本发明涉及使用一起反应的物质来制备用于诊断细胞传播疾病或倾向于这种疾病的药剂，该药物被皮内施用，并且诊断是基于正面在应用点的反应。

4. 发明申请

WO2013034264A1 L-FABP BASED DIAGNOSIS OF KIDNEY INJURY AFTER AN ACUTE EVENT OR AFTER A SURGICAL INTERVENTION 审中-公开
标题翻译：急性发作后或术后干预后的L-FABP诊断KIDNEY伤害
公开(公告)号：WO2013034264A1
公开(公告)日：2013-03-14
申请号：PCT/EP2012/003668
申请日：2012-09-01
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , HUEDIG, Hendrik , KIENTSCH-ENGEL, Rosemarie , RUTZ, Sandra
发明人： HUEDIG, Hendrik , KIENTSCH-ENGEL, Rosemarie , RUTZ, Sandra
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/53 , G01N2333/47 , G01N2800/347 , G01N2800/50
摘要： The present invention provides means and methods for diagnosing acute kidney injury associated after an acute event or after a surgical intervention based on the biomarker L-FABP. In addition, a method of predicting the risk of an individual to suffer from a kidney injury after an acute event or after a surgical intervention in the future is provided as well as corresponding uses and kits.
摘要翻译：本发明提供用于诊断在急性事件之后或在基于生物标志物L-FABP的外科手术后相关的急性肾损伤的方法和方法。此外，提供预测个体在急性事件之后或在将来进行外科手术后患有肾损伤的风险的方法以及相应的用途和试剂盒。

5. 发明申请

WO1997003704A2 IN VIVO DIABETES TEST 审中-公开
标题翻译：体内糖尿病测试
公开(公告)号：WO1997003704A2
公开(公告)日：1997-02-06
申请号：PCT/EP1996003192
申请日：1996-07-19
申请人： BOEHRINGER MANNHEIM GMBH , ENDL, Josef , GANZ, Manfred , STAHL, Peter , KIENTSCH-ENGEL, Rosemarie , JUNG, Günther-Gerhard , POZZILLI, Paolo , DONIE, Frederic
发明人： BOEHRINGER MANNHEIM GMBH
IPC分类号： A61K49/00
CPC分类号： G01N33/6893 , A61K49/0006 , C12N9/88 , G01N33/564 , G01N33/574 , G01N33/74 , G01N2800/042
摘要： The invention concerns the use of substances which react together to prepare an agent for the diagnosis of cell-transmitted diseases or a predisposition towards such diseases, the agent being applied intradermally and the diagnosis being made on the basis of the appearance or absence of a positive reaction at the point of application.
摘要翻译：本发明涉及使用自动反应物质用于制备药剂的用于蜂窝介导的疾病的诊断或对细胞介导的疾病的易感性，包括将所述试剂皮内和诊断阳性反应的发生或不存在的基础上是在施用部位。

6. 发明申请

WO2009033831A1 MYOGLOBIN AS EARLY PREDICTOR OF MYOCARDIAL INFARCTION 审中-公开
标题翻译： MYOGLOBIN作为心肌梗塞早期预后因素
公开(公告)号：WO2009033831A1
公开(公告)日：2009-03-19
申请号：PCT/EP2008/056605
申请日：2008-05-29
申请人： F. HOFFMANN- LA ROCHE AG , ROCHE DIAGNOSTICS GMBH , HESS, Georg , HÜDIG, Hendrik , KIENTSCH-ENGEL, Rosemarie , ZDUNEK, Dietmar
发明人： HESS, Georg , HÜDIG, Hendrik , KIENTSCH-ENGEL, Rosemarie , ZDUNEK, Dietmar
IPC分类号： G01N33/68 , G01N33/92
CPC分类号： G01N33/6887 , G01N2333/805 , G01N2800/324
摘要： The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac Troponin level, which is detectable, but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac Troponin level which is detectable, but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of myoglobin and, optionally, Heart-type fatty acid binding protein (H-FABP) in a sample of said subject and comparing the amount of myoglobin and, optionally, H-FABP to reference amounts. Also comprised by the present invention are kits or devices to carry out the methods of the present invention.
摘要翻译：本发明涉及一种用于诊断患有急性冠状动脉综合征且具有心肌肌钙蛋白水平的受试者的心肌梗塞的方法，其可检测但低于被认为是指示心肌梗死的水平。此外，本发明涉及用于识别易受心脏干预的受试者的方法，其中所述受试者患有急性冠状动脉综合征，并且具有心脏肌钙蛋白水平，其可检测但低于被认为是指示心肌梗死本发明的方法是基于在所述受试者的样品中测定肌红蛋白和任选的心脏型脂肪酸结合蛋白（H-FABP），并将肌红蛋白和任选的H-FABP的量与参考金额。本发明还包括用于实施本发明方法的试剂盒或装置。

7. 发明申请

WO1998015580A1 MONOCLONAL ANTIBODIES AGAINST A HUMAN ACT AND SERINE PROTEASE COMPLEX 审中-公开
标题翻译：抗人ACT的复合物与一种丝氨酸蛋白酶单克隆抗体
公开(公告)号：WO1998015580A1
公开(公告)日：1998-04-16
申请号：PCT/EP1997005556
申请日：1997-10-09
申请人： BOEHRINGER MANNHEIM GMBH , HÜBNER-PARAJSZ, Christa , SCHETTERS, Hartmut , KIENTSCH-ENGEL, Rosemarie , MEIER, Thomas , KAUFMANN, Martin , GALLUSSER, Andreas , DEEG, Rolf
发明人： BOEHRINGER MANNHEIM GMBH
IPC分类号： C07K16/38
CPC分类号： C07K14/705 , C07K16/38 , C07K16/40 , G01N33/57434
摘要： The invention relates to monoclonal antibodies against a human ACT and serine protease complex, preferably ACT-PSA presenting no cross reactivity to free, non-complexed human ACT and free, non-complexed PSA, as well as diagnostic test methods to detect serine protease ACT complexes, using these monoclonal antibodies.
摘要翻译：本发明涉及一种单克隆抗体针对人ACT的络合物和丝氨酸蛋白酶，优选ACT-PSA基本上没有交叉反应性，以释放，具有非络合的人ACT和自由的，未复合的PSA，以及诊断测试方法用于检测丝氨酸蛋白酶-ACT的络合物，特别是PSA-ACT使用单克隆抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式